CAR-T Cell Therapy Development for Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) presents a significant therapeutic challenge due to its aggressive nature and lack of common hormone receptors. At Alfa Cytology, we provide specialized preclinical CRO services to support the development of CAR-T cell therapies tailored for TNBC. Our integrated platform encompasses target validation, CAR construct design, in vitro testing, and in vivo efficacy evaluation-accelerating the translation of innovative immunotherapies toward clinical readiness.
Our Services
Target Identification and Validation
Screening and validation of TNBC-specific antigens suitable for CAR-T therapy, using transcriptomic, proteomic, and tumor tissue profiling tools.
CAR Construct Design & Optimization
Design and in vitro optimization of custom CAR constructs, including scFv engineering, costimulatory domain selection, and transduction efficiency testing.
In Vitro Functional Evaluation
Comprehensive assays to assess CAR-T cytotoxicity, cytokine release, proliferation, and persistence against TNBC cell lines.
In Vivo Efficacy Studies
Evaluation of CAR-T cell antitumor activity using xenograft and syngeneic TNBC mouse models, including biodistribution and tumor regression analysis.
Key Advantages
| TNBC-Focused Antigen Strategies | Selection of novel or underexplored tumor-associated antigens ensures enhanced specificity for the heterogeneity of triple-negative breast tumors. |
| Modular and Flexible CAR Design | CAR constructs are customized with modular domains to meet your preclinical goals—whether optimizing persistence, minimizing exhaustion, or improving safety profiles. |
| Physiologically Relevant Models | Our validated 2D, 3D, and in vivo models reflect the complex tumor microenvironment of TNBC, providing reliable platforms for therapeutic screening. |
| IND-Enabling Preclinical Packages | Comprehensive, publication-ready data packages are generated to support IND submissions and guide early-stage development decisions. |
Download our brochure to explore how our preclinical CAR-T services can advance your TNBC research. For customized project planning and technical consultation, please contact us directly.
Case Study - In Vitro CAR-T Evaluation
HER2 CAR-T cells were co-cultured with MDA-MB-231 cells at varying effector-to-target ratios. HER2-specific CAR-T cells specifically recognized HER2+ tumor cells, shown by significantly increased IFNγ secretion, while unmodified (NT) T cells did not induce mIFNg release (Fig.1). HER2-specific CAR-T cells selectively killed MDA-MB-231 cells, whereas non-transduced T cells showed no cytotoxicity (Fig.2). These results demonstrate HER2-specific CAR activates mouse T cells and triggers tumor killing via antigen-dependent mechanisms.
Fig.1 HER2 CAR or NT T cells were co-cultured with HER2+ MDA-MB-231 cells at various T cell to tumor cell ratios.
Fig.2 XTT-based cytotoxicity assay.
